Podrobno

Development, validation, and application of an HPLC method combined with an in vitro model for the determination of antibiotic binding to the haemoadsorber Cytosorb®
ID Kenda, Sara (Avtor), ID Gubenšek, Jakob (Avtor), ID Vovk, Tomaž (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (5,31 MB)
MD5: 0C8019A99046E1A9F154F4765EA1EC0D
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1420-3049/31/13/2337 Povezava se odpre v novem oknu

Izvleček
Supportive therapy with haemoadsorption is gaining popularity in critically ill patients, with the aim of reducing overinflammation triggered by the cytokine storm. The haemoadsorbers used are not specific for cytokines and also bind antibiotics. The aim of this study was to develop and validate a simple analytical method for the simultaneous determination of selected antibiotics and to develop an in vitro model for the quantification of their binding to the CytoSorb® haemoadsorber under conditions simulating sepsis. Imipenem (IMI), amoxicillin (AMO), cefepime (CEF), meropenem (MERO), vancomycin (VAN) and piperacillin (PIP) were measured in bovine plasma via precipitation with acetonitrile and liquid–liquid extraction with dichloromethane. The aqueous phase was collected and analysed using a C18 HPLC system under gradient conditions, with modulation of organic solvent content and mobile phase pH, and detection performed using a UV/Vis detector. The method was linear (r$^2$2 > 0.982) across investigated analytical ranges (1.0–100.0 µg/mL for AMO and VAN, 1.0–75.0 µg/mL for CEF, MERO and PIP and 2.5–100.0 µg/mL for IMI). Intra- and inter-day precision did not exceed 14% and accuracy ranged from 85.8% to 108.5%. Using the in vitro model, we showed that CytoSorb® significantly removed VAN and PIP, but not MERO. Further clinical studies are needed to establish the clinical significance of these findings and their impact on antibiotic exposure.

Jezik:Angleški jezik
Ključne besede:antibiotics, critically ill, CytoSorb®, gradient elution, haemoadsorption, hemoadsorption, in vitro model
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2026
Št. strani:14 str.
Številčenje:Vol. 31, iss. 13, art. 2337
PID:20.500.12556/RUL-184399 Povezava se odpre v novem oknu
UDK:61+615.33
ISSN pri članku:1420-3049
DOI:10.3390/molecules31132337 Povezava se odpre v novem oknu
COBISS.SI-ID:283660803 Povezava se odpre v novem oknu
Datum objave v RUL:06.07.2026
Število ogledov:191
Število prenosov:113
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Molecules
Skrajšan naslov:Molecules
Založnik:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:antibiotiki, kritično bolni, CytoSorb®, gradientna elucija, hemoadsorpcija, hemoadsorpcija, model in vitro, citokini, antibiotiki

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P1-0189
Naslov:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0323
Naslov:Ledvične bolezni in nadomestna zdravljenja

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj